Cardiac risk stratification is a critical process in assessing an individual's likelihood of developing cardiovascular complications and tailoring appropriate preventive measures. This method involves the systematic evaluation of various risk factors that contribute to heart-related issues, such as age, gender, family history, smoking habits, blood pressure, cholesterol levels, and existing medical conditions. By analyzing these factors, healthcare professionals can categorize individuals into different risk groups, ranging from low to high risk. This stratification enables the development of personalized intervention plans, including lifestyle modifications, medication, and regular monitoring, to mitigate the potential for cardiac events. Accurate risk assessment is instrumental in enhancing early detection and intervention, ultimately improving patient outcomes and reducing the overall burden of cardiovascular diseases. Regular updates to risk stratification guidelines ensure that healthcare providers stay abreast of the latest research and technological advancements, refining their ability to predict and manage cardiac risks effectively.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India